Analysis of antimalarial synergy between bestatin and endoprotease inhibitors using statistical response-surface modelling

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 11, 2001, Pages 3175-3181

  Gavigan, C S ^a   Machado, S G ^a   Dalton, J P ^a   Bell, A ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC PROTEINASE INHIBITOR; BESTATIN; CYSTEINE PROTEINASE INHIBITOR; HEMOGLOBIN; N [N (3 CARBOXYOXIRANE 2 CARBONYL)LEUCYL]AGMATINE; PEPSTATIN; PROTEINASE INHIBITOR;

ANTIMALARIAL ACTIVITY; ARTICLE; DRUG POTENTIATION; IC 50; MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEINASE INHIBITION; STANDARDIZATION;

ALGORITHMS; ANIMALS; ANTIMALARIALS; DRUG SYNERGISM; LEUCINE; MODELS, BIOLOGICAL; PEPSTATINS; PLASMODIUM FALCIPARUM; PROTEASE INHIBITORS;

EID: 0034775098     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.11.3175-3181.2001     Document Type: Article

References (34)

1. Plasmodium falciparum: Differential sensitivity in vitro to E-64 (cysteine protease inhibitor) and pepstatin A (aspartyl protease inhibitor)
2. Synergy, additivism and antagonism in immunosupression, a critical review
3. A method for testing synergy with any number of agents
4. The expected effect of a combination of agents: The general solution
5. Proteases as drug targets for the treatment of malaria
6. Identification of potent inhibitors of Plasmodium falciparum plasmepsin II from an encoded statine combinatorial library
7. Aminopeptidases from Plasmodium falciparum, Plasmodium chabaudi chabaudi and Plasmodium berghei
8. Identification and characterization of falcilysin, a metallopeptidase involved in haemoglobin catabolism within the malaria parasite Plasmodium falciparum
9. Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites
10. Haemoglobin metabolism in the malaria parasite Plasmodium falciparum
11. The antagonism between the actions of active substances
12. Role of aminopeptidases in haemoglobin degradation in Plasmodium falciparum-infected erythrocytes
13. Order and specificity of the Plasmodium falciparum haemoglobin degradation pathway
14. Haemoglobin degradation in the malaria parasite Plasmodium falciparum: An ordered process in a unique organelle
15. Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-β-D-arabinofuranosylcytosine
16. Measurement of the potencies of drug mixtures
17. Generation of haemoglobin peptides in the acidic digestive vacuole of Plasmodium falciparum implicates peptide transport in amino acid production
18. The problem of synergism and antagonism of combined drugs
19. A direct, general approach based on isobolograms for assessing the joint action of drugs in pre-clinical experiments
20. Plasmodium chabaudi chabaudi and Plasmodium falciparum: Inhibition of aminopeptidase and parasite growth by bestatin and nitrobestatin
21. Malaria vaccines: Multiple targets
22. Malaria, the submerged disease
23. Antimalarial effects of orally administered peptidyl cysteine protease inhibitors
24. Structure-based inhibitor design by using protein models for the development of antiparasitic agents
25. A malarial cysteine protease is necessary for haemoglobin degradation by Plasmodium falciparum
26. Toxicological studies on bestatin, I. Acute toxicity test in mice, rats, and dogs
27. Antimalarial synergy of cysteine and aspartic protease inhibitors
28. Statistical analysis of drug-drug and site-site interactions with isobolograms
29. Localization and characterization of haemoglobin-degrading aspartic proteinases from the malarial parasite Plasmodium falciparum
30. Disease problems in the third world
31. The efficacy of antifolate antimalarial combinations in Africa: A predictive model based on pharmacodynamic and pharmacokinetic analyses
32. Synergistic drug combinations in AIDS therapy: Dipyridamole-3′-azido-3′-deoxythymidine in particular and principles of analysis in general
33. Antimalarial drug resistance: The pace quickens
34. Strategies for the prevention of anti-malarial drug resistance: Rationale for combination chemotherapy for malaria